Renaissance Technologies’s Sonnet BioTherapeutics SONN Stock Holding History

Renaissance Technologies’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-5,469	Closed	-$76K	–	4047
2023 Q4	$76K	Buy	5,469 +3,088	+130%	+$42K	﹤0.01%	3372
2023 Q3	$55K	Buy	2,381 +711	+43%	+$37.4K	﹤0.01%	3386
2023 Q2	$144K	Buy	1,670 +1,578	+1,715%	+$111K	﹤0.01%	3379
2023 Q1	$6K	Buy	+92	New	+$14.9K	﹤0.01%	3908
2022 Q3	–	Sell	-32	Closed	-$22K	–	4375
2022 Q2	$22K	Sell	32 -699	-96%	-$501K	﹤0.01%	4109
2022 Q1	$677K	Buy	731 +595	+438%	+$503K	﹤0.01%	2986
2021 Q4	$138K	Buy	136 +89	+189%	+$128K	﹤0.01%	3623
2021 Q3	$70K	Buy	+47	New	+$105K	﹤0.01%	3359
2020 Q1	–	Sell	-1	Closed	-$34K	–	3758
2019 Q4	$34K	Hold	1	–	–	﹤0.01%	3424
2019 Q3	$49K	Hold	1	–	–	﹤0.01%	3329
2019 Q2	$39K	Buy	+1	New	+$85K	﹤0.01%	3472
2019 Q1	–	Hold	0	–	–	–	3386

Other funds holding SONN

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PWMG

Private Wealth Management Group Princeton, New Jersey $381M AUM 19.19% 1-Year Est. Return

Renaissance Technologies's SONN Position: Q1 2024 in Review

Renaissance Technologies sold out of Sonnet BioTherapeutics (SONN) in Q1 2024, closing a stake of 5,469 shares — an estimated $76K sold.

Renaissance Technologies first reported a position in SONN in Q2 2019 and held it in 11 quarters. The position peaked at $677K in Q1 2022. 9 funds tracked by Wall St. Rank hold SONN as of Q1 2024.

Renaissance Technologies reported no remaining Sonnet BioTherapeutics position as of Q1 2024 after selling out during the quarter.
Renaissance Technologies sold 5,469 Sonnet BioTherapeutics shares in Q1 2024, an estimated $76K.
Renaissance Technologies first reported a position in Sonnet BioTherapeutics in Q2 2019 and held it in 11 quarters.
Renaissance Technologies's Sonnet BioTherapeutics position peaked at $677K in Q1 2022.
9 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q1 2024.

Based on Renaissance Technologies's 13F filing for Q1 2024, filed 13 May 2024.